9-ING-41 + gemcitabine

**9-ING-41 + gemcitabine** is an investigational drug combination in oncology consisting of 9-ING-41, a first-in-class small-molecule maleimide-based potent and selective inhibitor of Glycogen Synthase Kinase-3 beta (GSK-3β), and gemcitabine, a nucleoside analog chemotherapeutic commonly used in solid tumors[1][2][3][4][5][6][7][8]. 9-ING-41 works by inhibiting GSK-3β, a kinase implicated in tumor progression, chemotherapy resistance, and cellular survival via modulation of key oncogenic pathways including NF-κB, beta-catenin, cyclin D1, c-Myc, and p53[1][2][3][5][7]. The combination aims to improve antitumor efficacy and overcome resistance to chemotherapy, with clinical development focused primarily on metastatic or locally advanced pancreatic cancer, among other solid tumors and hematologic malignancies[1][2][3][4][6].

Other names

9-ING-41 plus gemcitabine9-ING-41 combined with gemcitabine